Close
American Drug Delivery & Formulation Summit
Xylem

Press Releases

Pharmaceutical packaging: Advantages of digital printing technology in blister packaging

Producing pharmaceutical products for the global market is hugely challenging and complex. When a drug is set to be sold in multiple countries, it needs to be packaged in a way which accommodates the regulatory requirements and specific artwork demands...

Pathogen engineered to self destruct underlies cancer vaccine platform

A team of investigators has developed a cancer vaccine technology using live, attenuated pathogens as vectors. A feature of the vaccine causes these bacteria to self-destruct once they've done their job, making it safe for use in humans. The...

Artificial DNA can control release of active ingredients from drugs

A drug with three active ingredients that are released in sequence at specific times: Thanks to the work of a team at the Technical University of Munich (TUM), what was once a pharmacologist's dream is now much closer to...

SpringWorks and GSK sign clinical trial collaboration agreement

SpringWorks Therapeutics has signed an agreement to assess its nirogacestat in combination with GlaxoSmithKlineโ€™s (GSK) belantamab mafodotin to treat patients with relapsed or refractory multiple myeloma. Under the clinical trial collaboration agreement, GSK will sponsor and conduct an adaptive Phase...

Velabs Therapeutics Announces 3 Million Series B Financing to Advance its Functional Antibody Screening Programme

Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, announced the closing of a โ‚ฌ3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional...

AbbVie Announces US FDA Lifts Partial Clinical Hold on Phase 3 Study of Venetoclax in Patients with Multiple Myeloma Positive for the Genetic Abnormality

AbbVie , a research-based global biopharmaceutical company announced that the U.S. FDAย  has lifted the partial clinical hold placed on CANOVA (M13-494), a Phase 3 trial evaluating venetoclax (VENCLEXTAยฎ OR VENCLYXTOยฎ) for the investigational treatment of relapsed/refractory multiple myeloma....

Parexel Strengthens Risk-Based Monitoring Offering with CluePointsโ€™ New Advanced Statistical Capabilities

Parexel, a leading provider of Clinical, Consulting and Commercial solutions to accelerate the development of innovative new therapies to improve the worldโ€™s health. Announcedย  its strategic collaboration with CluePoints, an industry-leading provider of Risk-Based Study Execution...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate ยป